Nasif Wesam Ahmed, El-Moursy Ali Abeer Shaker, Hasan Mukhtar Mohammed, Alhuzali Aali Marzouq H, Yahya Alnashri Yahya Ahmed, Ahmed Gadah Ziyad Ishaq, Edrees Eyyad Adeeb A, Albarakati Hussam Abdulaziz Mabruk, Muhji Aloufi Hussam Saud
Biochemistry Department, Faculty of Medicine, Umm Al-Qura University, Mecca, Saudi Arabia.
Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute, Sadat City University, Sadat City, Egypt.
Anemia. 2022 Mar 8;2022:9104209. doi: 10.1155/2022/9104209. eCollection 2022.
The review explores the findings of previous studies to elucidate the association between levels of D-dimer and COVID-19 severity and prognosis. In addition, we assessed the efficiency of anticoagulant therapies in reducing COVID-19 severity and improving the prognosis of the patients.
A comprehensive literature review was conducted using MEDLINE/PubMed databases, Scopus, and Web of Science with the help of keywords "COVID-19," "D-Dimer," "Thrombosis," "Fibrin network," "Anticoagulant therapy," "Inflammation," and "disease severity." Based on all these articles and clinical experience, a scoping review was constructed and the full texts of the articles that were retrieved were accessed.
A D-dimer is a complex protein molecule that is formed during plasmin-mediated degradation of the fibrin network. Thus, it serves as a marker of thrombotic activity. On the other hand, in addition to severe respiratory distress and reduction in pulmonary gas exchange, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) also triggers prothrombotic changes in the infected individuals. The levels of D-dimer have been postulated to be positively associated with the degree of disease severity among COVID-19 patients.
It has been postulated that D-dimer could potentially be used as a biomarker to predict the prognosis and outcome of COVID-19 patients at the time of admission to hospitals and facilitate more personalized and efficient clinical management that could significantly reduce the mortality rate of such patients and allow more rapid recovery.
本综述探讨既往研究结果,以阐明D - 二聚体水平与新型冠状病毒肺炎(COVID - 19)严重程度及预后之间的关联。此外,我们评估了抗凝治疗在降低COVID - 19严重程度及改善患者预后方面的效果。
借助关键词“COVID - 19”“D - 二聚体”“血栓形成”“纤维蛋白网络”“抗凝治疗”“炎症”及“疾病严重程度”,使用MEDLINE/PubMed数据库、Scopus和科学网进行全面的文献综述。基于所有这些文章及临床经验构建了一项范围综述,并获取了检索到的文章全文。
D - 二聚体是一种复杂的蛋白质分子,在纤溶酶介导的纤维蛋白网络降解过程中形成。因此,它可作为血栓形成活性的标志物。另一方面,除了严重的呼吸窘迫和肺气体交换减少外,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)还会在感染个体中引发促血栓形成变化。据推测,D - 二聚体水平与COVID - 19患者的疾病严重程度呈正相关。
据推测,D - 二聚体有可能用作生物标志物,以预测COVID - 19患者入院时的预后和结局,并促进更个性化、高效的临床管理,从而显著降低此类患者的死亡率并实现更快康复。